MGI gene sequencing company

Location: Home /  News Center

MGI’s DNBSEQ-T7 Powers YUCEBIO to Accelerate the Development of Clinical Application of Tumor Immunodiagnosis and Treatment

Release date:2021-02-24Writer:MGIViews:345Share

MGI’s sequencing platform in the YUCEBIO’s lab

 

SHENZHEN, China, Feb 24, 2021-- MGI’s ultra-high-throughput gene sequencer, DNBSEQ-T7, is installed in Yukang Medical Laboratory of YUCEBIO. YUCEBIO and MGI will be working with each other again after their cooperation in 2018 and 2019. In the cooperation, YUCEBIO will promote the development of clinical application of tumor immunodiagnosis and treatment based on the technical advantages of DNBSEQ-T7, and combined with its own advantages in tumor immune markers, high-quality neoantigen prediction and biological big data.

 

“High-quality core tools are fundamental to life science research and clinical applications. With the rapid development of the sequencing technology, the monopoly by foreign companies is over. In 2018, powered by MGI’s high-throughput sequencing platform, MGISEQ - 2000, we improved the sequencing data output from Gb to Tb. Meanwhile, we were the first to build a tumor immune diagnosis and treatment technology and service platform in China, covering the upstream and downstream of tumor immune industry chain, thanks to the stable operation and high-quality data output of MGISEQ - 2000.” Said Gao Zhibo, CEO of YUCEBIO, “After 2 years of clinical application, the performance of MGISEQ-2000 has been verified in YUCEBIO. MGI’s core sequencing technology DNBSEQTM can produce higher quality data with lower duplicate rate and index hopping. Therefore, as the market demand increases and the product line is upgraded, we have introduced the ultra-high throughput sequencing platform DNBSEQ-T7.”

 

In 2019, MGI and YUCEBIO reached a strategic cooperation agreement

 

“Over the last two decades, the field of oncology genomics has witnessed phenomenal growth that wouldn’t have been possible without the joint efforts from the oncology clinical genomic testing service companies. YUCEBIO is one of the leading companies in the field of tumor immunotherapy in China. We started our cooperation in 2018. We have witnessed the rapid development of YUCEBIO in the past two years, and we are glad that our sequencer has played a role in this process.” said Jiang Hui, COO of MGI, “Currently, DNBSEQ-T7 will fully support YUCEBIO's product line, including clinical companion diagnostics, dynamic monitoring and clinical research services for malignant tumors.”

 

Dongfang Wu, COO of YUCEBIO, said that with the addition of DNBSEQ-T7, YUCEBIO will build a multi-dimensional omics platform as the foundation to push the China’s Anti-cancer · Ladder Program into the 2.0 era.

 

Launching ceremony of China’s Anti-cancer · Ladder Program in 2017

 

The China’s Anti-cancer · Ladder Program was launched in 2017, aiming to build an anti-cancer “Ladder” based on big data of tumor immunity and accelerating the clinical application of tumor immunotherapy. In 2021, with the advent of the era of comprehensive immunotherapy, China Anti-cancer · Ladder Program also enters a new era and a new mode.

 

With the mission of “making cancer immunotherapy more effective”, YUCEBIO aims to work together with MGI to provide accurate testing services with higher quality and lower price for Chinese cancer patients.

 

“DNBSEQ-T7 can help biotechnology companies to further reduce the production cost, improve product quality and shorten the delivery cycle to maximize the technological advantages to expedite the industry development and grow into the world’s leading biotechnology companies.” Said Fang Xiao, General Manager of MGI Greater China Area.

 

About “China Anti-cancer · Ladder Program”

“China’s Anti-Cancer · Ladder Program” is the first genomic cooperation project specifically for cancer immunotherapy in China, which was jointly launched by YUCEBIO and Academician Zhan Qimin. The core goal of this program is to establish the first 10,000-level 3D tumor database in China, which includes not only the relations between gene mutations and tumors, but also the influence of the immune micro-environment on tumors, and then correlates the data of tumor genome, tumor microenvironment and clinical treatment.

 

About Yukang Medical Laboratory

Shenzhen Yukang Medical Laboratory is an independent third-party medical laboratory approved by Shenzhen Municipal Health Commission. As a medical laboratory under YUCEBIO, Yukang Medical Lab has always followed the principle of “scientific, accurate, rigorous and innovative” to ensure the accuracy, reliability and safety of testing. For three years, it has passed the quality assessment and ability verification by domestic and foreign authoritative institutions such as NCCL, CAP and EMQN with outstanding achievements. In January 2021, it obtained the CAP certificate, making it one of the internationally renowned laboratories.

 

Yukang medical laboratory is equipped with MGI’s DNBSEQ - T7, MGISEQ - 2000, NanoString spatio-temporal platform, QuantStudio 3D digital PCR platform, qPCR platform, pathologic and immunohistochemical platform. The services cover the whole workflow from the sample receiving, management and preparation, sequencing analysis, and results interpretation to report. The fully automated data analysis and interpretation system can update real-time genetic information database and clinical interpretation database. The laboratory provides high quality, high-precision clinical testing services, and multi-dimensional, all-round medical research services.